XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis
XBiotech Inc. (XBIT)
Last xbiotech inc. earnings: 8/9 03:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
xbiotech.com/about/investors.html
Company Research
Source: GlobeNewswire
AUSTIN, Texas, Sept. 13, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced that it has completed the first cohort of its open label pilot study in Atopic Dermatitis (AD). In the first phase of the study, 9 patients received a low dose (200mg/weekly) over a short course of treatment (4 weeks). Multiple secondary endpoints used to assess efficacy showed significant improvements. The 200mg subcutaneous injections were well tolerated in the cohort. The study will now begin enrollment of 20 patients to receive 400mg weekly doses over an 8 week treatment period. The Study Chair, Dr. Francisco Kerdel, commented, “Although this is a small sample, I am encouraged by the benefit observed in AD patients treated with bermekimab. I look forward to the results from the second cohort in patients who will receive a higher dose and longer treatment duration with bermekimab.” Bermekimab treatment was associated with the following statistically significant outcomes for assessment of
Show less
Read more
Impact Snapshot
Event Time:
XBIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XBIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XBIT alerts
High impacting XBiotech Inc. news events
Weekly update
A roundup of the hottest topics
XBIT
Sec Filings
- 5/1/24 - Form ARS
- 5/1/24 - Form DEFA14A
- 5/1/24 - Form DEF
- XBIT's page on the SEC website